Condition
Complement Abnormality
Total Trials
4
Recruiting
1
Active
1
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (1)
P 2 (2)
Trial Status
Recruiting1
Completed1
Unknown1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04183101Phase 2Recruiting
Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy
NCT04725812Phase 2Terminated
Complement Regulation to Undo Systemic Harm in Preeclampsia
NCT04103489Phase 1Completed
The Use of Eculizumab in HELLP Syndrome
NCT05258643Not ApplicableUnknownPrimary
The Role of Natural Killer, Complement and T-lymphocytes in COVID-19 Disease, a Prospective Monocentric Study
Showing all 4 trials